TickerFacts.

Entera Bio Ltd. (ENTX): Cost of Revenue

Annual figures by period end, from SEC filings.

$42.0K
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
-25.4%
3-year compound annual growth
-32.5%
5-year compound annual growth
$373.0K2020-12-31: $300.0K2021-12-31: $373.0K2022-12-31: $101.0K2023-12-31: $02024-12-31: $172.0K2025-12-31: $42.0K$42.0K
2020-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$42.0K-75.6%2026-03-27, From 2025-01-01
2024-12-31$172.0Kn/a2026-03-27, From 2024-01-01
2023-12-31$0-100.0%2025-03-28, From 2023-01-01
2022-12-31$101.0K-72.9%2024-03-08, From 2022-01-01
2021-12-31$373.0K+24.3%2023-03-31, From 2021-01-01
2020-12-31$300.0Kn/a2022-03-08, From 2020-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Entera Bio Ltd. (ENTX)2025-12-31$42.0K-75.6%
VivoSim Labs, Inc. (VIVS)2026-03-31$0-100.0%
Zivo Bioscience, Inc. (ZIVO)2024-12-31$108.3K+575.0%
Creative Medical Technology Holdings, Inc. (CELZ)2025-12-31$2.2K-50.1%
Pluri Inc. (PLUR)2026-06-30$563.0K-17.4%
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$3.96M+220.1%
Outlook Therapeutics, Inc. (OTLK)2025-09-30$1.36Mn/a
Humacyte, Inc. (HUMA)2025-12-31$9.70Mn/a
Dyadic International Inc (DYAI)2025-12-31$2.32M+94.2%

Compare ENTX, VIVS, ZIVO, CELZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗